Fady Ibraham  Malik net worth and biography

Fady Malik Biography and Net Worth

EVP of Cytokinetics

Fady has been with Cytokinetics since our inception in 1998, serving in a variety of positions focused on building our cardiovascular and skeletal muscle programs from their conception, playing a key role in the preclinical and clinical progress of these programs. He is currently our Executive Vice President of Research and Development.

Since 2000, Fady has held an appointment in the Cardiology Division of the University of California, San Francisco, where he is currently a Clinical Professor. He was also a practicing Interventional Cardiologist at the San Francisco Veterans Administration Medical Center for over 18 years.

Dr. Malik received a B.S. from the University of California, Berkeley and his Ph.D. and M.D. from the University of California, San Francisco.

Fady is a native San Franciscan who enjoys travel, outdoor sports such as running and skiing, and spending time with his wife and three kids.

What is Fady Ibraham Malik's net worth?

The estimated net worth of Fady Ibraham Malik is at least $7.41 million as of July 9th, 2024. Dr. Malik owns 131,004 shares of Cytokinetics stock worth more than $7,406,966 as of July 22nd. This net worth estimate does not reflect any other investments that Dr. Malik may own. Additionally, Dr. Malik receives a salary of $839,660.00 as EVP at Cytokinetics. Learn More about Fady Ibraham Malik's net worth.

How old is Fady Ibraham Malik?

Dr. Malik is currently 60 years old. There are 4 older executives and no younger executives at Cytokinetics. The oldest executive at Cytokinetics is Dr. James A. Spudich Ph.D., Co-Founder & Member of Scientific Advisory Board, who is 82 years old. Learn More on Fady Ibraham Malik's age.

What is Fady Ibraham Malik's salary?

As the EVP of Cytokinetics, Incorporated, Dr. Malik earns $839,660.00 per year. The highest earning executive at Cytokinetics is Mr. Robert I. Blum, CEO, President, Principal Financial Officer & Director, who commands a salary of $1,330,000.00 per year. Learn More on Fady Ibraham Malik's salary.

How do I contact Fady Ibraham Malik?

The corporate mailing address for Dr. Malik and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on Fady Ibraham Malik's contact information.

Has Fady Ibraham Malik been buying or selling shares of Cytokinetics?

During the past quarter, Fady Ibraham Malik has sold $408,070.00 in shares of Cytokinetics stock. Most recently, Fady Ibraham Malik sold 7,300 shares of the business's stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $55.90, for a transaction totalling $408,070.00. Following the completion of the sale, the executive vice president now directly owns 131,004 shares of the company's stock, valued at $7,323,123.60. Learn More on Fady Ibraham Malik's trading history.

Who are Cytokinetics' active insiders?

Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (CEO), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.

Are insiders buying or selling shares of Cytokinetics?

During the last year, insiders at the biopharmaceutical company sold shares 38 times. They sold a total of 432,853 shares worth more than $25,036,596.51. The most recent insider tranaction occured on July, 15th when Director B Lynne Parshall sold 5,000 shares worth more than $279,100.00. Insiders at Cytokinetics own 3.4% of the company. Learn More about insider trades at Cytokinetics.

Information on this page was last updated on 7/15/2024.

Fady Ibraham Malik Insider Trading History at Cytokinetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/9/2024Sell7,300$55.90$408,070.00131,004View SEC Filing Icon  
6/25/2024Sell7,300$53.72$392,156.00133,004View SEC Filing Icon  
6/11/2024Sell7,788$53.04$413,075.52135,004View SEC Filing Icon  
5/7/2024Sell15,547$65.11$1,012,265.17137,056View SEC Filing Icon  
4/9/2024Sell32,605$74.31$2,422,877.55138,567View SEC Filing Icon  
3/5/2024Sell32,604$67.56$2,202,726.24138,973View SEC Filing Icon  
2/6/2024Sell32,605$79.30$2,585,576.50142,973View SEC Filing Icon  
1/4/2024Sell15,678$86.98$1,363,672.44146,973View SEC Filing Icon  
11/9/2023Sell2,500$35.40$88,500.00150,664View SEC Filing Icon  
10/12/2023Sell2,500$35.89$89,725.00153,164View SEC Filing Icon  
9/14/2023Sell2,500$34.86$87,150.00155,664View SEC Filing Icon  
7/13/2023Sell2,500$35.37$88,425.00160,664View SEC Filing Icon  
6/8/2023Sell2,500$38.07$95,175.00163,164View SEC Filing Icon  
5/11/2023Sell1,787$39.50$70,586.50165,396View SEC Filing Icon  
5/3/2023Sell7,000$40.00$280,000.00167,183View SEC Filing Icon  
4/13/2023Sell4,000$34.21$136,840.00167,183View SEC Filing Icon  
3/9/2023Sell4,000$39.10$156,400.00171,183View SEC Filing Icon  
2/9/2023Sell4,000$43.73$174,920.00152,589View SEC Filing Icon  
1/12/2023Sell4,000$40.47$161,880.00156,589View SEC Filing Icon  
11/10/2022Sell4,000$38.04$152,160.00164,346View SEC Filing Icon  
10/13/2022Sell21,513$47.28$1,017,134.64168,346View SEC Filing Icon  
9/8/2022Sell21,500$51.88$1,115,420.00168,346View SEC Filing Icon  
7/14/2022Sell21,500$43.43$933,745.00168,346View SEC Filing Icon  
5/12/2022Sell13,987$37.54$525,071.98168,084View SEC Filing Icon  
4/7/2022Sell23,148$42.58$985,641.84168,084View SEC Filing Icon  
3/10/2022Sell26,852$37.82$1,015,542.64View SEC Filing Icon  
12/9/2021Sell29,166$36.49$1,064,267.34View SEC Filing Icon  
10/14/2021Sell2,000$37.73$75,460.00View SEC Filing Icon  
9/9/2021Sell2,000$31.43$62,860.00View SEC Filing Icon  
8/12/2021Sell2,000$32.60$65,200.00View SEC Filing Icon  
7/8/2021Sell2,000$19.48$38,960.00View SEC Filing Icon  
6/10/2021Sell2,000$21.48$42,960.00View SEC Filing Icon  
5/13/2021Sell2,000$24.42$48,840.00View SEC Filing Icon  
4/8/2021Sell2,000$23.39$46,780.00View SEC Filing Icon  
3/11/2021Sell2,000$19.90$39,800.00View SEC Filing Icon  
2/11/2021Sell1,632$23.34$38,090.88View SEC Filing Icon  
1/14/2021Sell12,500$19.25$240,625.00View SEC Filing Icon  
12/10/2020Sell1,052$20.13$21,176.76View SEC Filing Icon  
11/12/2020Sell1,231$17.15$21,111.65View SEC Filing Icon  
10/8/2020Sell1,258$17.45$21,952.10View SEC Filing Icon  
9/10/2020Sell995$22.85$22,735.75View SEC Filing Icon  
8/13/2020Sell599$21.85$13,088.15View SEC Filing Icon  
7/9/2020Sell1,587$26.96$42,785.52View SEC Filing Icon  
12/5/2019Sell1,500$9.80$14,700.00121,350View SEC Filing Icon  
11/7/2019Sell1,500$9.98$14,970.00122,850View SEC Filing Icon  
10/3/2019Sell1,500$11.22$16,830.00122,067View SEC Filing Icon  
9/5/2019Sell1,500$13.69$20,535.00123,567View SEC Filing Icon  
8/8/2019Sell1,500$13.52$20,280.00125,067View SEC Filing Icon  
7/11/2019Sell1,500$11.26$16,890.00126,567View SEC Filing Icon  
6/6/2019Sell1,500$10.31$15,465.00128,067View SEC Filing Icon  
5/2/2019Sell1,500$8.29$12,435.00129,567View SEC Filing Icon  
4/4/2019Sell1,500$8.31$12,465.00131,067View SEC Filing Icon  
3/7/2019Sell1,500$5.98$8,970.00132,567View SEC Filing Icon  
2/7/2019Sell1,500$7.28$10,920.0084,067View SEC Filing Icon  
1/10/2019Sell1,500$7.31$10,965.0085,567View SEC Filing Icon  
12/6/2018Sell1,500$7.38$11,070.0087,067View SEC Filing Icon  
11/1/2018Sell1,500$6.68$10,020.0088,567View SEC Filing Icon  
10/4/2018Sell1,500$9.14$13,710.0090,067View SEC Filing Icon  
9/6/2018Sell1,500$8.00$12,000.0091,567View SEC Filing Icon  
8/2/2018Sell1,500$6.85$10,275.0093,067View SEC Filing Icon  
7/5/2018Sell1,500$9.05$13,575.0094,567View SEC Filing Icon  
6/7/2018Sell3,000$8.95$26,850.0096,067View SEC Filing Icon  
11/1/2017Sell7,321$13.39$98,028.1947,540View SEC Filing Icon  
12/29/2016Sell5,633$12.36$69,623.883,361View SEC Filing Icon  
12/30/2014Sell21,630$6.73$145,569.90View SEC Filing Icon  
See Full Table

Fady Ibraham Malik Buying and Selling Activity at Cytokinetics

This chart shows Fady Ibraham Malik's buying and selling at Cytokinetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cytokinetics Company Overview

Cytokinetics logo
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $57.42
Low: $55.66
High: $57.69

50 Day Range

MA: $54.14
Low: $47.86
High: $60.60

2 Week Range

Now: $57.42
Low: $25.98
High: $110.25


1,436,834 shs

Average Volume

2,568,761 shs

Market Capitalization

$6.02 billion

P/E Ratio


Dividend Yield